94-26120. Public Meeting on the Development of Smoking Prevention and Cessation; Clinical Practice Guideline  

  • [Federal Register Volume 59, Number 203 (Friday, October 21, 1994)]
    [Unknown Section]
    [Page 0]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 94-26120]
    
    
    [[Page Unknown]]
    
    [Federal Register: October 21, 1994]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Agency for Health Care Policy and Research
    
     
    
    Public Meeting on the Development of Smoking Prevention and 
    Cessation; Clinical Practice Guideline
    
        The Agency for Health Care Policy and Research (AHCPR) and the 
    Centers for Disease Control and Prevention (CDC) announce that a public 
    meeting will be held to receive comments and information pertaining to 
    the development of the clinical practice guideline on Smoking 
    Prevention and Cessation. The guideline will focus on the intervention 
    therapies used for nicotine dependence treatment and the evidence of 
    their effectiveness. The guideline is being developed by a private-
    sector panel of health care experts and consumers. The panel is 
    supported by AHCPR.
        A notice announcing that AHCPR was arranging for the development of 
    this clinical practice guideline was published in the Federal Register 
    on December 15, 1992 (Vol. 57, No. 241). That notice invited 
    nominations for experts and consumers to serve on the panel that is 
    developing the guideline.
        A public meeting to provide an opportunity for interested parties 
    to contribute relevant information and comments, including research in 
    areas relevant to the guideline, will be held as follows:
        Meeting: Smoking Prevention and Cessation.
        Date: November 9, 1994.
        From: 9:00 a.m.-12:00 p.m.
        Location: Bethesda Marriott Hotel, Grand Ballroom, 5151 Pooks Hill 
    Road; Bethesda, MD 20814.
        Phone: (301) 897-9400.
    
    Background
    
        The AHCPR is charged, under Title IX of the Public Health Service 
    Act, with enhancing the quality, appropriateness, and effectiveness of 
    health care services, and access to such services. The AHCPR 
    accomplishes its goals through the establishment of a broad base of 
    scientific research, and through the promotion of improvements in 
    clinical practice and in the organization, financing, and delivery of 
    health care services. (See 42 U.S.C. 299-299c-6 and 1320-12.)
        In keeping with its legislative mandates, AHCPR arranges for the 
    development, periodic review, and update of clinically relevant 
    guidelines that may be used by physicians, nurses, other health care 
    providers, educators, and consumers to assist in determining how 
    diseases, disorders, and other health care conditions can most 
    effectively and appropriately be prevented, diagnosed, treated, and 
    clinically managed. Medical review criteria, standards of quality, and 
    performance measures are then developed based on the guidelines 
    produced.
        Section 912 of the Act (42 U.S.C. 299b-1(b)), as amended, requires 
    that the guidelines:
        1. Be based on the best available research and professional 
    judgment;
        2. Be presented in formats appropriate for use by physicians, 
    nurses, other health care providers, medical educators, medical review 
    organizations, and consumers;
        3. Be presented in treatment-specific or condition-specific forms 
    appropriate for use in clinical practice, education programs, and 
    reviewing quality and appropriateness of medical care;
        4. Include information on the risks and benefits of alternative 
    strategies for prevention, diagnosis, treatment, and management of the 
    particular health condition(s); and
        5. Include information on the costs of alternative strategies for 
    prevention, diagnosis, treatment, and management of the particular 
    health condition(s), where cost information is available and reliable.
        Section 914 of the Act (42 U.S.C. 299b-3(a)), as amended, 
    identifies factors to be considered in establishing priorities for 
    guidelines, including the extent to which the guidelines would:
        1. Improve methods for disease prevention;
        2. Improve methods of diagnosis, treatment, and clinical 
    management, and thereby benefit a significant number of individuals;
        3. Reduce clinically significant variations among clinicians in the 
    particular services and procedures utilized in making diagnoses and 
    providing treatment; and
        4. Reduce clinically significant variations in the outcomes of 
    health care services and procedures.
        Also, in accordance with Title IX of the PHS Act and section 1142 
    of the Social Security Act, the AHCPR Administrator is to assure that 
    the needs and priorities of the Medicare program are reflected 
    appropriately in the agenda and priorities for development of 
    guidelines and guideline updates.
    
    Arrangements for the November 9, 1994 Public Meeting on Smoking 
    Prevention and Cessation
    
        Representatives of organizations and other individuals are invited 
    to provide relevant written comments and information, and make a brief 
    (5 minutes or less) oral statement to the panel. Individuals and 
    representatives who would like to attend must register with Cheryl 
    Campbell, Panel Manager, Technical Resources, Inc., (TRI), at the 
    address set out below by October 26, 1994, and indicate whether they 
    plan to make an oral statement. A written copy of the oral statement, 
    comments, and information should be submitted to TRI by October 26, 
    1994. If more requests to make oral statements are received than can be 
    accommodated between 9:00 a.m. and 12:00 p.m. on November 9, 1994, the 
    chairperson will allocate speaking time in a manner which ensures, to 
    the extent possible, that a range of views of health care 
    professionals, consumers, product manufacturers, and pharmaceutical 
    manufacturers are presented. Those who cannot be granted their 
    requested speaking time because of time constraints are assured that 
    their written comments will be considered when making a decision 
    regarding the development of the guideline.
        If sign language interpretation or other reasonable accommodation 
    for a disability is needed, please contact Technical Resources, Inc. by 
    October 26, 1994, at the address below.
        Registration should be made with, and written materials submitted 
    to: Ms. Cheryl Campbell, Panel Manager, Technical Resources, Inc., 3202 
    Tower Oaks Boulevard, Rockville, Maryland 20852, Phone: (301) 231-5250, 
    Fax: (301) 231-6377.
    
    For Additional Information
    
        Additional information on the guideline development process is 
    contained in the AHCPR Program Note, ``Clinical Practice Guideline 
    Development,'' dated August 1993. This document describes AHCPR's 
    activities with respect to clinical practice guidelines including the 
    process and criteria for selecting panels. This document may be 
    obtained from the AHCPR Publications Clearinghouse, P.O. Box 8547, 
    Silver Spring, MD 20907; or call Toll-Free: 1-800-358-9295.
        Also, information can be obtained by contacting Douglas B. Kamerow, 
    M.D., M.P.H. Director, Office of the Forum for Quality and 
    Effectiveness in Health Care, Agency for Health Care Policy and 
    Research, Willco Building, 6000 Executive Boulevard, Suite 310, 
    Rockville, MD 20852, Phone 301-594-4015, Fax: 301-594-4027.
    
        Dated: October 17, 1994.
    Clifton R. Gaus,
    Administrator.
    [FR Doc. 94-26120 Filed 10-20-94; 8:45 am]
    BILLING CODE 4160-90-P
    
    
    

Document Information

Published:
10/21/1994
Department:
Agency for Healthcare Research and Quality
Entry Type:
Uncategorized Document
Document Number:
94-26120
Dates:
November 9, 1994.
Pages:
0-0 (1 pages)
Docket Numbers:
Federal Register: October 21, 1994